BioWorld

May 28, 2004

Acadia, Critical Therapeutics Price In 'Not A Robust Market'

Two more biotech companies went public Thursday, but as has been the case lately, their offerings brought in less than first expected. (BioWorld Today) Read More

With MyVax In Phase III, Genitope Raising $51.8M In Public Offering

Chiron Gains Vaccine Contract Against Avian Influenza Strain

Syrrx Receives Milestone From Biogen Idec In Target Agreement

Holiday Notice

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...